I have found, more often than not, that the FQ data trail leads us into areas where we do not want to go; areas that we would normally avoid, if it were up to us. Areas that are ugly inconvenient truths.
Recently an internal memo dated April 17, 2013, issued by the Food and Drug Administration’s Center Drug Evaluation and Research, Office of Surveillance and Epidemiology, was obtained through the freedom of information act shows the FQs in a damning light.
When researchers have the mindset that the current usable formulary of FQ’s is a goal to reach based on safety and efficacy then the premise of their research is flawed.
A simple three step action that logically links FQ’s to the ability to initiate delayed adverse "late effect" reactions. There are no grand leaps of faith or conjecture required to link the steps.
This insidious response from the medication creates the perfect storm in which it disguises itself so the patient and the doctor do not associate the adverse reaction with the medication.